| Sepsis is the final common pathway to death for severe infectious diseases worldwide.
The present trial aimed to investigate the effects of nano-curcumin supplementation
on hematological indices in critically ill patients with sepsis. Fourteen ICU-admitted
patients were randomly allocated into either nano-curcumin or placebo group for
10 days. The blood indices, serum levels of inflammatory biomarker and presepsin as
well as nutrition status, and clinical outcomes were assessed before the intervention
and on days 5 and 10. White blood cells, neutrophils, platelets, erythrocyte sedimentation rate (ESR), and the levels of interleukin-8 significantly decreased in the nanocurcumin group compared to the placebo after 10 days of intervention (p = .024,
p = .045, p = .017, p = .041, and p = .004, respectively). There was also a marginal
meaningful decrease in serum presepsin levels in the intervention group compared
to the placebo at the end of the study (p = .054). However, total lymphocyte count
showed a significant increase in the nano-curcumin group compared to the placebo
at the end-point (p = .04). No significant differences were found in the level of lymphocyte and the ratios of neutrophil/lymphocyte and platelet/lymphocyte between
the study groups. Moreover, no significant between-group differences were observed
for other study outcomes, post-intervention. Collectively, nano-curcumin may be a
useful adjuvant therapy in critically ill patients with sepsis. However, further trials are
suggested to examine the effects of nano-curcumin in the management of sepsis and
its complications |